Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Primary Dysautonomias 1Pancreatic Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1High Risk Prostate Cancer 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Receptors, Androgen × Clear all
NCT05700903 2026-03-02

ARCH

University of Colorado, Denver

Phase 4 Completed
10 enrolled
Genitourinary

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT06758882 2025-01-06

STAPLE

A.O.U. Città della Salute e della Scienza

Phase 2 Recruiting
94 enrolled
Genitourinary

High Risk Prostate Cancer

NCT02138383 2021-08-17

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
25 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡